Company: DARE
Filing Date: 2025-04-24
Form Type: DEF 14A
Source: 0001401914-25-000014
Chunk: 68

Company: Dare Bioscience, Inc.
Filing Date: 2025-04-24
Form: DEF 14A
Chunk 68
---
 the Company and the value of such award or vesting or payment, when combined with all other payments in the nature of compensation contingent on such change in control, equals or exceeds the dollar limit provided in Code Section 280G (generally, this dollar limit is equal to three times the five year historical average of the employee’s annual compensation as reported on Form W-2), then the entire amount exceeding the employee’s average annual compensation will be considered to be an excess parachute payment. The recipient of an excess parachute payment must pay a 20% excise tax on this excess amount, for which the Company must withhold, and the Company cannot deduct the excess amount from its taxable income.

#### New Plan Benefits
No awards have been granted to any officer, director, employee or consultant under the 2022 Plan that are contingent upon the approval of the 2022 Plan Amendment by our stockholders. We anticipate that awards may be granted in the discretion of our Board or the Compensation Committee under the 2022 Plan out of the additional shares of common stock that would be available under the 2022 Plan if the 2022 Plan Amendment is approved by our stockholders; however, the number and type of awards that may be so granted has not yet been determined. However, pursuant to our current compensation arrangement for non-employee directors, and based on the current composition of our Board, the aggregate number of our common shares subject to awards that will automatically be granted on an annual basis to all of our current directors who are not executive officers as a group will be 22,500 shares (which consists of a stock option to purchase 4,500 shares for each of our current non-employee directors). For additional information regarding our current compensation arrangement for non-employee directors, please see “Director Compensation” above.

#### OUR BOARD RECOMMENDS A VOTE "FOR" PROPOSAL 4.
2025 Proxy Statement | Page 49

### OTHER MATTERS
As of the time of preparation of this Proxy Statement, we do not know of any matter to be acted upon at the Annual Meeting other than the matters described in this Proxy Statement. If any other matter properly comes before the Annual Meeting, however, the proxy holders will vote the proxies thereon in accordance with the recommendation of our Board.

#### DELINQUENT SECTION 16(a) REPORTS
Under Section 16(a) of the Exchange Act, our directors and executive officers, and beneficial owners of more than 10% of our common stock (collectively,